Mylo100 mg+100 mg+1 mg)/3 ml

Established / Guideline-Supported Uses

• Treatment and prevention of vitamin B1 (thiamine), B6 (pyridoxine), and B12 (cobalamin) deficiency, particularly in patients with inadequate dietary intake, malabsorption, chronic alcohol use, or increased requirements.

Adjunct Symptomatic Uses (Guideline/Practice-Supported, Not Curative)

• Mylo is widely used as adjunct symptomatic support for peripheral neuropathy, neuritis, and neuralgia-type pain of nutritional, diabetic, alcoholic, or other origin (e.g. sciatica, trigeminal neuralgia), typically alongside treatment directed at the underlying cause.
• Mylo is not a substitute for definitive treatment of the condition causing the neuropathy (e.g. glycemic control in diabetic neuropathy); the underlying cause requires separate medical evaluation and management.

Note: Mylo does not replace prescription therapy for pain or nerve disease and should be used as directed by a physician as part of a broader treatment plan.

Vitamin B1 + B6 + B12 is a fixed combination of three neurotropic B-vitamins, typically supplied as:

• Vitamin B1 (Thiamine) - as thiamine hydrochloride or thiamine mononitrate
• Vitamin B6 (Pyridoxine) - as pyridoxine hydrochloride
• Vitamin B12 (Cobalamin) - as cyanocobalamin (or, in some formulations, methylcobalamin)

Vitamin B1 + B6 + B12 is available in oral (tablet/capsule) and, in some markets, injectable dosage forms; exact strengths vary by brand and formulation.

Mylo is a combination of three essential B-group vitamins that work together to support normal nervous system function, energy metabolism, and red blood cell formation. Thiamine (B1), pyridoxine (B6), and cobalamin (B12) are each individually essential nutrients, and the combination is formulated to provide neurotropic support that is greater than any single vitamin alone, particularly for nerve-related symptoms.

Mylo is commonly used both to correct or prevent deficiency of these vitamins and, at appropriate doses, as adjunct therapy for symptoms of peripheral nerve irritation or damage (neuropathy, neuritis, neuralgia) arising from various causes, including diabetes, chronic alcohol use, and nutritional deficiency.

Vitamin B1 + B6 + B12 combines three B-vitamins with complementary neurological and metabolic roles:

• Thiamine (B1) acts as a cofactor (as thiamine pyrophosphate) in carbohydrate metabolism and in the citric acid cycle, supplying energy required for normal neuronal function; deficiency impairs nerve conduction and can cause peripheral neuropathy (as in beriberi).
• Pyridoxine (B6), as pyridoxal-5-phosphate, is a cofactor for enzymes involved in amino acid metabolism and in the synthesis of neurotransmitters (e.g. serotonin, dopamine, GABA) and heme; it supports normal nerve signaling.
• Cobalamin (B12) is required for DNA synthesis, myelin formation around nerve fibers, and red blood cell maturation; deficiency can cause demyelination, peripheral neuropathy, and megaloblastic anemia.

Together, the components of Vitamin B1 + B6 + B12 are proposed to have synergistic neurotropic and analgesic-adjunct effects on damaged or irritated peripheral nerves, supporting nerve repair and reducing neuropathic symptoms, in addition to correcting any underlying deficiency.

Oral Mylo tablets/capsules should be swallowed whole with water, preferably with or after a meal. If an injectable form of Mylo is prescribed, it must only be given intramuscularly by a qualified healthcare professional. Do not alter the dose, frequency, or duration without consulting the physician.

• Levodopa (without a decarboxylase inhibitor): Pyridoxine (vitamin B6) in Mylo can increase the peripheral breakdown of levodopa, reducing its effectiveness for Parkinson's disease. This interaction is not clinically significant when levodopa is combined with a decarboxylase inhibitor such as carbidopa.
• Phenytoin and phenobarbital: Pyridoxine may modestly lower plasma levels of these anticonvulsants in some patients; clinical monitoring is advised with prolonged high-dose use.
• Isoniazid, hydralazine, penicillamine: These drugs increase pyridoxine requirements/turnover; co-administration with Mylo is often used therapeutically to prevent B6-deficiency neuropathy, but should be guided by a physician.
• Chloramphenicol: May blunt the hematologic (red blood cell) response to vitamin B12 therapy; monitor response if used concurrently.

No other clinically significant drug interactions are well established for Mylo at standard doses.

Mylo is generally well tolerated at recommended doses. Reported adverse effects are usually mild and include:

• Nausea, mild gastrointestinal discomfort
• Headache
• Allergic skin reactions (rash, itching) in a small number of patients
• Rarely, hypersensitivity reactions, including injection-site reactions with parenteral forms

Peripheral sensory neuropathy has been reported with prolonged, high-dose pyridoxine (vitamin B6) use above recommended doses (see Precautions and Warnings).

At standard recommended doses, the individual B-vitamins in Mylo are generally considered acceptable for use during pregnancy and lactation, as they are also present in prenatal multivitamins. However, Mylo should be used during pregnancy and breastfeeding only if clearly needed and as directed by a physician, since doses above nutritional requirements have not been fully evaluated for safety in pregnancy. Injectable forms containing benzyl alcohol as a preservative are generally not recommended during pregnancy and lactation; oral forms are preferred if supplementation is needed. Consult a physician before use.

• High-dose, prolonged pyridoxine (B6) use: Taking more than the recommended dose of Mylo for extended periods has been associated, in rare cases, with peripheral sensory neuropathy - paradoxically similar to the symptoms Mylo is often used to help manage at appropriate doses. Do not exceed the recommended dose or duration without medical guidance.
• Masking of B12 deficiency: Because folate and B12 metabolism are interlinked, use of Mylo without proper laboratory evaluation may mask the blood-count (hematologic) signs of an underlying B12 deficiency while neurological damage continues; patients with suspected significant B12 deficiency should be properly evaluated by a physician.
• Levodopa therapy: Patients on levodopa without a decarboxylase inhibitor should avoid Mylo unless advised by a physician (see Interactions).
• Mylo is generally well tolerated at standard doses; discontinue and seek medical advice if signs of an allergic reaction occur.

Significant toxicity from standard oral doses of Mylo is uncommon. Very high, prolonged doses of pyridoxine (B6) may cause peripheral sensory neuropathy. In case of a suspected overdose or accidental ingestion of a large amount of Mylo, seek immediate medical attention or contact a poison control center; treatment is generally supportive and symptomatic. Do not attempt to manage a suspected overdose at home without medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric patients: Mylo is not routinely used in children except for confirmed vitamin deficiency states; safety and efficacy of high-dose neuropathy-support regimens have not been established in children, and use should be individualized and supervised by a physician.

Elderly patients: No specific dose adjustment is generally required, but elderly patients may have a higher prevalence of B12 deficiency and should be evaluated appropriately; use standard doses as directed by a physician.

Renal/hepatic impairment: See Dosage and Administration; no well-established dose adjustment is required for standard oral doses, but medical supervision is advised with prolonged high-dose use.

Duration of treatment with Mylo depends on the indication: short courses may be used to correct mild deficiency, while adjunct therapy for peripheral neuropathy or neuralgia symptoms may continue for several weeks under medical supervision. Prolonged high-dose use, particularly beyond the duration recommended by the physician, should be avoided due to the risk of pyridoxine-associated peripheral neuropathy. Follow the physician's advice on how long to continue treatment.

Vitamin B-complex combination; Neurotropic vitamin supplement

Vitamin B1 + B6 + B12 works through the complementary actions of thiamine (energy metabolism and nerve conduction support), pyridoxine (amino acid metabolism and neurotransmitter synthesis), and cobalamin (myelin formation and red blood cell maturation), together supporting normal peripheral nerve function and helping correct or prevent deficiency-related nerve and blood abnormalities.

Mylo is not commonly used in children except to treat or prevent a confirmed deficiency of vitamin B1, B6, or B12. Safety and efficacy for neuropathy/neuralgia symptom support have not been established in the pediatric population. If a physician determines that a child requires Mylo, dosing must be individualized based on age, weight, and clinical need, and use should be closely supervised.